Business Update16 Jul 2025, 01:11 pm
Suven Life Sciences Announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder
AI Summary
Suven Life Sciences, a clinical stage biopharmaceutical company, announced that the first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant, a novel oral a4B2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of Major Depressive Disorder (MDD). The trial builds on the positive results of a Phase-2a trial, which demonstrated favorable safety and clinically meaningful improvement in depressive symptoms. The Phase-2b trial is being conducted exclusively in the USA under FDA IND, with topline data expected in the second half of 2026.
Key Highlights
- Suven Life Sciences has randomized the first patient in its Phase-2b clinical trial of Ropanicant for Major Depressive Disorder.
- The Phase-2b trial is a randomized, double-blind, placebo-controlled study that will enroll approximately 195 patients across 35 sites in the USA.
- The trial builds on the positive results of a Phase-2a trial, which demonstrated favorable safety and clinically meaningful improvement in depressive symptoms.
- The Phase-2b trial is being conducted exclusively in the USA under FDA IND, with topline data expected in the second half of 2026.
- Ropanicant is a novel, potent and selective a4B82 nAChR antagonist, and is being developed for the treatment of MDD.